CARDIAC chronotropic effects of sleep‐disordered breathing in patients with heart failure

2020 ◽  
Author(s):  
Gian Domenico Pinna ◽  
Maria Teresa La Rovere ◽  
Elena Robbi ◽  
Luigi Tavazzi ◽  
Roberto Maestri
2015 ◽  
Vol 2015 ◽  
pp. 1-1
Author(s):  
Anna Kazimierczak ◽  
Paweł Krzesiński ◽  
Krystian Krzyżanowski ◽  
Grzegorz Gielerak

2012 ◽  
Vol 8 (1) ◽  
pp. 40
Author(s):  
Masaaki Takeuchi ◽  
Nobuhiko Haruki ◽  
Yutaka Otsuji ◽  
◽  
◽  
...  

Patients with heart failure frequently have associated sleep-disordered breathing, which has a significant negative impact on cardiac function. Echocardiography is a versatile modality for the management of heart failure. Recent developments in speckle tracking analysis have demonstrated that two-dimensional strain has potential for the quantification of subclinical abnormalities in ventricular function. This article outlines the utility of speckle tracking echocardiography in patients with heart failure and sleep-disordered breathing.


2005 ◽  
Vol 11 (9) ◽  
pp. S294
Author(s):  
Umpei Yamamoto ◽  
Masahiro Mohri ◽  
Kohtaro Abe ◽  
Kenji Miyata

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A267-A267
Author(s):  
S I Patel ◽  
M Vasquez ◽  
F Huang ◽  
D Combs ◽  
S Parthasarathy

Abstract Introduction Some studies have shown a benefit while others have shown possible harm in patient outcomes when using positive airway pressure therapy (PAP) for treating sleep disordered breathing (SDB) in patients with heart failure (HF). The goal of this study was to evaluate the number of HF-related and all-cause related hospitalizations in patients with HF and SDB on various forms of PAP therapy versus those on no PAP therapy. Methods Administrative claims data from the Truven Health MarketScan Database from 1/1/2005- 10/31/2015 were analyzed. Those included were at least 21 years old, were continuously enrolled for 12 months before and 6 months after their index date (date of PAP prescription), had at least two distinct HF-related claims and were prescribed PAP therapy (n=1,324,414). To model the relationship between each device and hospitalization risk, and to account for the longitudinal and correlated nature of these binary outcome data, generalized estimating equations with binomial family, logit link, and unstructured correlation structure were used. Results There were a total of 12,538 patients on Bilevel-PAP, 2,700 patients on bilevel-PAP with backup rate, and 57,405 patients on CPAP, and 73,353 patients with HF and comorbid sleep apnea who were not on any treatment. The reduction in HF-related hospitalization for patients with HF and comorbid SDB treated with bilevel-PAP therapy (0.28; 95% CI 0.26, 0.31) was greater than that in patients receiving CPAP (OR 0.46 95% CI 0.43, 0.49), bilevel PAP with back-up rate (0.39; 95% CI 0.32, 0.49), or no PAP treatment (OR 0.54; 95%CI 0.50, 0.57)(P<0.01). Similar trend was observed for all-cause related hospitalizations. All results were adjusted for propensity score and other relevant confounders. Conclusion In claims-based analysis of patients with HF and comorbid SDB, bilevel PAP treatment was associated with reduced hospitalizations when compared to CPAP therapy or no PAP treatment. Support Phillips Respironics


Sign in / Sign up

Export Citation Format

Share Document